DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

BLA 125554/S-017 and S-018

SUPPLEMENT APPROVAL

Bristol-Myers Squibb Company
Attention: Linda Gambone, Ph.D.
Director, US Regulatory
Route 206 & Province Line Road
Mail stop D32-01
Princeton, NJ 08543

Dear Dr. Gambone:

Please refer to your Supplemental Biologic License Applications (sBLAs), dated February 5 and 12, 2016, respectively, received February 5 and 12, 2016, respectively, and your amendments, submitted under section 351(a) of the Public Health Service Act for Opdivo® (nivolumab) Injection, for intravenous infusion, 40 mg/4 mL and 100 mg/10 mL (10 mg/mL) single-use vials.

These Prior Approval supplemental biologic applications provide updates to remove or modify the currently approved recommended dosage regimen and include a new recommended dosage regimen for nivolumab to 240 mg intravenously every two weeks for the currently approved indications for treatment of renal cell carcinoma (RCC), metastatic melanoma, and non-small cell lung cancer (NSCLC). The following sections of the prescribing information were updated: HIGHLIGHTS; DOSAGE and ADMINISTRATION (2.1, 2.2, and 2.3) and CLINICAL PHARMACOLOGY (12.2, 12.3).

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling

[21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at: http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for the treatment of patients with unresectable or metastatic melanoma has an orphan drug designation, you are exempt from this requirement for this indication.

In addition, we are waiving the pediatric study requirements for the treatment of patients with non-small cell lung cancer (NSCLC) and advanced renal cell carcinoma (RCC) because necessary studies are impossible or highly impracticable since the disease/condition does not exist in children.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at: http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at: http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, contact Ms. Missiratch (Mimi) Biable, Senior Regulatory Health Project Manager, at (301) 796-0154 or missiratch.biable@fda.hhs.gov for matters related to sBLA-017 and Ms. Amy Tilley, Senior Regulatory Health Project Manager, at (301) 796-3994 or amy.tilley@fda.hhs.gov for matters related to sBLA-018.

Sincerely,

{See appended electronic signature page}

Patricia Keegan, M.D.
Director
Division of Oncology Products 2
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

Geoffrey Kim, M.D.
Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

PATRICIA KEEGAN
09/13/2016

GEOFFREY S KIM
09/13/2016